TESSLIFT SOFT Is Presented at the 106th The Congress of Japanese Society of Aesthetic Surgery (JSAS)

TOKYO, JAPAN, MAY.18, 2018 -- TESSLIFT CO., LTD., a leading provider of tissue approximation technologies for Plastic & Reconstruction markets, has underwent a succesful launching symposium at one of the most presitigious Aesthetic Surgery Conferences in Japan, the Congress of Japanese Society of Aesthetic Surgery (JSAS). This year, the 106th JSAS was led by the president, Hajime Watahiki (Shinagawa Comsetic Surgery, Tokyo). The TESSLIFT's exlusive distributor in Japan has invited Dr. MIN Kim (ZISHEL CLINIC, Seoul) for the lecture, which was presented at the final session of the congress. The lecture was guided by the Chairperson, Dr. Yohio Ikeda (Tokyo Skin Cell Clinic) who has also contributed to the final developement of the TESSLIFT SOFT. With the extensive network of more than 300 clinics in Japan, the distributor is working with the TESSLIFT effectively by assigning the most renowned doctors in Japan to represent the products as the Key Opion Leaders. The promotion of the products through Japan will eventually succeed in achieving the widespread of the TESSLIFT users.

TESSLIFT, the premium mesh implant, is deployed into the SMAS layers to suspend the surrounding tissues via tissue ingrowths technology into its pores. The barbs in the implant provides the initial holding strength to suspend the tissues. The mesh and its tissue ingrowth of the surrounding tissues provide the major contributions in the later phases. This world's first innovative technology is protected under the intellectual property rights in over 48 countries.

ABOUT ZISHEL GROUP

ZISHEL GROUP is established to R&D, market, and distribute the novel medical technologies for Plastic and Reconstruction and Aesthetics. In connection with more than 23 international medical chains and +11450 private clinics, we have the mega-size distribution channels in over 52 countries covered by +35 blockbuster distributors worldwide. The majority of our executives were both educated and trained in the United States. They lead with excellence via unique leadership styles over our staffs and have propitious relationships with internationally recognized professors, physicians, and healthcare professionals worldwide. Our key differentiator is our continual investments for R&D activities under variety of applications. In the fast-changing healthcare environment, we challenge ourselves to adapt to new trends and lead developments for novel solutions tailored to our clients' needs.

WEBSITE. www.zishel.com | EMAIL. info@zishel.com

ABOUT

TESSLIFT is a privately owned medical device company, dedicated to the development and commercialization of the world's first invented mesh suspension implants. TESS is an abbreviation for Tissue Elevation Suspension System. For research initiatives underway, we desire to use our novel technology to expand its use to meet other unmet clinical needs. With that in mind, we are closely cooperating with surgeons and biomedical engineers to maximize the safety and effectiveness of our products.

WEBSITE. www.tesslift.com | EMAIL. info@tesslift.com

EDITOR

EILEEN KIM, ZISHEL GROUP

CONTACT. +1-851-0186 [US]


HQ. 907HO SK LEADERS VIEW BLDG, DOGOK-DONG GANGNAM-GU, SEOUL, KOREA

BD / R&D CENTER. 1F A, PAX TOWER, 609 EONJU-RO, GANGNAM-GU, SEOUL, KOREA

COPYRIGHT © 2020 ZISHEL MEDICAL. ALL RIGHTS RESERVED.

  • Facebook
  • Instagram
  • YouTube
  • 링크드 인 - 회색 원